Innovative Cancer Treatments: Partnership with Roche
The State Enterprise "Medical Procurement" has announced new initiatives in the production of drugs for combating cancer diseases.
According to a post by the press service on Facebook, an agreement with the international pharmaceutical company Roche for the localization of innovative cancer drug production was signed during the Ukraine Recovery Conference 2025 in Rome.
"For the first time, our state enterprise is becoming a full partner of a global leader in the development of innovative drugs! Under the investment agreement, the Swiss company Roche will supply medicines to Ukraine in bulk, ready for packaging. Our branch 'Medpostachannya' will handle their final packaging, labeling, and distribution to patients," the statement said.
This partnership will significantly reduce drug costs and increase the number of patients receiving modern treatments.
"According to Roche's estimates, over the next five years, the investment agreement will provide medicines for more than 5,800 patients," the State Enterprise "Medical Procurement" noted.
Specifically, they will procure drugs for the two most common types of cancer in Ukraine:
- Atezolizumab (“Tecentriq”) for the treatment of non-small cell lung cancer;
- Pertuzumab + Trastuzumab (“Phesgo”) for the treatment of HER2-positive breast cancer.
The first Ukrainian patients will receive locally produced medicines as early as 2027.
This collaboration promises significant cost reductions for medicines, the development of pharmaceutical production in Ukraine, and sustained access to treatment.
On July 10-11, the fourth International Conference on Ukraine Recovery (URC2025) is taking place in Rome, with participation from the President of Ukraine and heads of European states.
The forum will continue a series of high-level political events focused on the rapid recovery and long-term reconstruction of Ukraine, which is suffering from external aggression. This time, the Ukrainian delegation will focus on presenting practical projects that are already being implemented even in wartime conditions.
